Fresenius SE & Co. KGaA (FSNUF)

UPDATE 2-Fresenius raises outlook on strong quarterly results, exits Vamed

German healthcare group Fresenius first-quarter results beat expectations, the company said on Wednesday, citing strong performance at its Kabi and Helios businesses, prompting it to raise its full-year outlook. First-quarter earnings before interest and tax (EBIT) were 633 million euros ($680 million), above analysts' expectations of 606 million euros, according to a consensus of forecasts from Vara Research. In a bid to get leaner, Fresenius also said that it would sell its investment unit, Fresenius Vamed, completing its portfolio restructuring.